<DOC>
	<DOCNO>NCT00345579</DOCNO>
	<brief_summary>The primary phase study evaluate safety Hib-MenCY-TT vaccine compare control group receive license Hib conjugate vaccine , co-administered Pediarix® healthy infant 2 , 4 , 6 month age . This protocol post deal objective &amp; outcome measure primary phase study . The objective &amp; outcome measure Booster phase present separate protocol posting ( NCT number = 00345683 ) . The Protocol Posting update order comply FDA Amendment Act , Sep 2007</brief_summary>
	<brief_title>Safety Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine , Given 2 , 4 , 6 12 15 Months Age</brief_title>
	<detailed_description>Pediarix/Infanrix Penta Prevnar co-administered subject study group accord 2 , 4 , 6 month schedule concomitantly study vaccine .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 6 12 week age time first vaccination . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Born 36 week gestation . Infants receive previous dose hepatitis B vaccine receive 1 dose hepatitis B vaccine administer least 30 day prior enrolment . Infants may receive birth dose Bacillus CalmetteGuérin ( BCG ) vaccine . Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . Planned administration/ administration vaccine foreseen study protocol within 30 day first dose study vaccine ( ) . Previous vaccination Neisseria meningitidis , Haemophilus influenzae type b , diphtheria , tetanus , pertussis , and/or poliovirus ; one previous dose hepatitis B vaccine . In country ( y ) Prevnar provide GSK Biologicals , previous vaccination Prevnar . History Neisseria meningitidis , Haemophilus influenzae type b , diphtheria , tetanus , pertussis , hepatitis B , and/or poliovirus disease . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine , include dry natural latex rubber . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrollment . Administration immunoglobulins and/or blood product since birth plan administration study period . Concurrent participation another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prophylaxis</keyword>
	<keyword>Neisseria meningitidis Vaccines , conjugate</keyword>
	<keyword>Infants</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>H. influenzae type B vaccine</keyword>
	<keyword>Humans</keyword>
	<keyword>Safety</keyword>
</DOC>